Vaderis was not the only company pushing toward late-stage execution this week—Definium’s psychedelic program also notched another Phase 3 win, while separate funding news highlighted continued investor appetite for difficult-to-treat conditions. Definium reported meaningful symptom improvement in a Phase 3 generalized anxiety disorder study as it prepares for a second pivotal trial.